Additionally, we quantified markers associated with immunotherapy response and prognosis in melanoma patients [27, 28], such as PD-1, PD-L1, CTLA-4 and major histocompatibility complex (MHC) class-II HLA-DR. The gene discussed is CD274; the disease is melanoma.